Corvus Pharmaceuticals, Inc. (CRVS)
Stock Price:
$4.20 USD
-0.03 (-0.71%)
Updated Aug 4, 2020 8:00 AM EDT - Market open
Key Info
| Market Cap |
117.40M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-45.60M |
| Shares Out |
28.04M |
| EPS (ttm) |
-1.55 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$4.20 |
| Previous Close |
$4.23 |
| Change ($) |
-0.03 |
| Change (%) |
-0.71% |
| Day's Open |
4.16 |
| Day's Range |
4.00 - 4.40 |
| Day's Volume |
15,984 |
| 52-Week Range |
1.01 - 6.88 |
More Stats
| Market Cap |
117.40M |
| Enterprise Value |
60.90M |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.04M |
| Float |
13.89M |
| EPS (basic) |
-1.55 |
| EPS (diluted) |
-1.55 |
| FCF / Share |
-1.29 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
424,168 |
| Short Ratio |
0.24 |
| Short % of Float |
9.63% |
| Beta |
2.04 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.99 |
| Revenue |
n/a |
| Operating Income |
-46.99M |
| Net Income |
-45.60M |
| Free Cash Flow |
-37.97M |
| Net Cash |
56.50M |
| Net Cash / Share |
2.02 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-35.11% |
| ROE |
-64.91% |
| ROIC |
-81.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
5 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$9.20*
(119.05% upside)
Low
6.00
Current: $4.20
High
15.00
Target: 9.20
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | - | - | - | - | - |
| Operating Income | -48.85 | -49.22 | -56.52 | -36.98 | -13.77 | -0.16 |
| Net Income | -46.67 | -46.94 | -55.66 | -36.38 | -31.34 | -0.16 |
| Shares Outstanding | 29.35 | 27.51 | 20.49 | 15.42 | 0.37 | 0.17 |
| Earnings Per Share | -1.59 | -1.71 | -2.72 | -2.36 | -83.86 | -0.95 |
| Operating Cash Flow | -37.32 | -40.99 | -46.21 | -27.86 | -11.33 | -0.10 |
| Capital Expenditures | -0.03 | -0.36 | -0.27 | -2.20 | -1.75 | - |
| Free Cash Flow | -37.35 | -41.34 | -46.48 | -30.06 | -13.08 | -0.10 |
| Cash & Equivalents | 77.98 | 115 | 90.06 | 135 | 94.39 | 12.52 |
| Total Debt | 3.19 | - | - | - | - | - |
| Net Cash / Debt | 74.79 | 115 | 90.06 | 135 | 94.39 | 12.52 |
| Assets | 83.65 | 118 | 94.78 | 140 | 98.46 | 12.53 |
| Liabilities | 12.54 | 7.90 | 9.94 | 7.35 | 3.78 | 2.68 |
| Book Value | 71.11 | 110 | 84.84 | 133 | -31.10 | -0.16 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Corvus Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
52 |
| CEO |
Richard A. Miller |
Stock Information
| Ticker Symbol |
CRVS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CRVS |
| IPO Date |
March 23, 2016 |
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.